Evidence‑Based Management of Anxiety in Alzheimer’s Disease

Non‑Pharmacologic First‑Line Strategies

Structured environmental and behavioral interventions—such as predictable daily routines, reduced sensory overstimulation, and clear orientation cues—reduce anxiety levels in patients with Alzheimer’s disease. 1
Optimizing treatment of comorbid medical conditions (e.g., pain, infections) helps mitigate anxiety symptoms in this population. 1

High‑quality, person‑centered psychosocial interventions are recommended as the first‑line approach for preventing and treating behavioral and psychological symptoms of dementia; pharmacologic therapy should be reserved for short‑term, carefully monitored use only. 3

Selective serotonin reuptake inhibitors (SSRIs) and serotonin‑norepinephrine reuptake inhibitors (SNRIs) are considered first‑line agents for anxiety in elderly Alzheimer’s patients, offering demonstrated efficacy, good tolerability, and a superior safety profile compared with alternative drug classes. 1

Low‑dose olanzapine (2.5–5 mg/day) may be employed for severe, dangerous anxiety that has not responded to first‑line therapy; a controlled analysis showed a greater reduction in NPI anxiety scores versus placebo (mean difference − 2.05, p = 0.034). 4
Antipsychotic use is justified only when:

Benzodiazepines are listed on the American Geriatrics Society Beers Criteria as potentially inappropriate for older adults because they increase the risk of cognitive impairment, falls, fractures, sedation, and withdrawal syndromes. 5
Cholinesterase inhibitors (e.g., rivastigmine, donepezil, galantamine) are not indicated for anxiety and may paradoxically provoke anxiety or agitation as side effects. 8

Start antipsychotics at the lowest possible dose and titrate only to the minimum effective amount tolerated. 4
Assess therapeutic response with quantitative measures (e.g., NPI anxiety score) at 4 weeks. 4
If no clinically significant improvement is observed after a 4‑week trial at an adequate dose, taper and discontinue the medication. 4
If clinically significant side effects develop, re‑evaluate risk‑benefit and consider tapering or stopping the drug. 4
For patients who respond positively, periodically reassess the need for continued treatment through discussion with the patient or surrogate decision‑makers. 4

Do not use antipsychotics as first‑line treatment without first exhausting non‑pharmacologic approaches. 3 4
Do not continue ineffective medications beyond 4–6 weeks of adequate dosing. 4
Do not prescribe benzodiazepines given their significant adverse‑event profile in this population. 5
Do not overlook underlying medical conditions that may be contributing to anxiety symptoms. 1
Do not use cholinesterase inhibitors specifically for anxiety management, as they may worsen agitation. 1 8